Opinion|Videos|November 15, 2024
Roflumilast: Mechanism, and Use for Proactive AD Management
Key Takeaways
- PDE4 inhibitors vary in selectivity, binding affinity, and pharmacokinetics, affecting therapeutic outcomes and adverse effects.
- Differences in isoform selectivity and tissue distribution influence efficacy and safety profiles of PDE4 inhibitors.
Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.
Advertisement
Episodes in this series
- What are some common misconceptions about the mechanism of PDE4 inhibitors that you encounter in clinical practice?
- Please explain why all PDE4 inhibitors are not created equal. How might these differences impact efficacy and safety profile?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
3
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
4
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
5